{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:37:17Z","timestamp":1771846637098,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The most recent studies published or initiated in the last 18 months, investigating cannabidiol in the treatment of symptoms of schizophrenia and related conditions are summarized, including observed tolerability and reported side-effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent studies focused on patients with sub-acute psychotic syndromes of schizophrenia, clinical high-risk state for psychosis (CHR-P), or frequent cannabis users, as well as cognitive functioning in chronic schizophrenia. There is further, although not consistent evidence for cannabidiol-reducing positive symptoms, but not negative symptoms. Evidence for improvement of cognition was weaker, with one study reporting a worsening. Regarding side effects and tolerability, cannabidiol induced sedation in one study, with the other studies indicating good tolerability, even at high doses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Recent clinical trials added further evidence for an antipsychotic potential of cannabidiol. In general, studies following trial designs as suggested by regulators in schizophrenia are needed in sufficient numbers to clarify the safety and efficacy of cannabidiol herein. In addition, such studies will further elucidate its ability to target specific aspects of the syndrome, such as negative or cognitive symptoms. Furthermore, aiming for an add-on treatment with cannabidiol will require further studies to identify potentially useful or even harmful combinations.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/yco.0000000000000596","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T12:28:04Z","timestamp":1582115284000},"page":"185-191","source":"Crossref","is-referenced-by-count":29,"title":["Cannabidiol as a treatment option for schizophrenia: recent evidence and current studies"],"prefix":"10.1097","volume":"33","author":[{"given":"Julie","family":"Schoevers","sequence":"first","affiliation":[{"name":"University Medical Centre Utrecht, Utrecht, The Netherlands"},{"name":"Brain and Mind Centre, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith E.","family":"Leweke","sequence":"additional","affiliation":[{"name":"Brain and Mind Centre, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen University, Goettingen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. Markus","family":"Leweke","sequence":"additional","affiliation":[{"name":"Brain and Mind Centre, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230925","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global Epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr Bull"},{"key":"R2-20230925","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatr"},{"key":"R3-20230925","doi-asserted-by":"crossref","first-page":"7","DOI":"10.9758\/cpn.2018.16.1.7","article-title":"Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies","volume":"16","author":"Tripathi","year":"2018","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"R4-20230925","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/schbul\/sbr004","article-title":"Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review","volume":"38","author":"Sommer","year":"2012","journal-title":"Schizophr Bull"},{"key":"R5-20230925","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41537-018-0064-6","article-title":"Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis","volume":"4","author":"Sinkeviciute","year":"2018","journal-title":"NPJ Schizophr"},{"key":"R6-20230925","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fphar.2016.00422","article-title":"Cannabidiol as a potential new type of an antipsychotic. a critical review of the evidence","volume":"7","author":"Rohleder","year":"2016","journal-title":"Front Pharmacol"},{"key":"R7-20230925","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/ja01865a080","article-title":"Isolation of cannabinol, cannabidiol and quebrachitol from red oil of Minnesota wild hemp","volume":"62","author":"Adams","year":"1940","journal-title":"J Am Chem Soc"},{"key":"R8-20230925","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol Psychiatry"},{"key":"R9-20230925","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/sni.sni_45_18","article-title":"Review of the neurological benefits of phytocannabinoids","volume":"9","author":"Maroon","year":"2018","journal-title":"Surg Neurol Int"},{"key":"R10-20230925","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl Psychiatry"},{"key":"R11-20230925","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1192\/bjp.bp.107.046649","article-title":"Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis","volume":"192","author":"Morgan","year":"2008","journal-title":"Br J Psychiatry"},{"key":"R12-20230925","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3389\/fphar.2018.00901","article-title":"Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia","volume":"9","author":"Peres","year":"2018","journal-title":"Front Pharmacol"},{"key":"R13-20230925","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.schres.2015.01.015","article-title":"Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol","volume":"164","author":"Gomes","year":"2015","journal-title":"Schizophr Res"},{"issue":"(2\u20133)","key":"R14-20230925","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2005.02.040","article-title":"Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice","volume":"512","author":"Moreira","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"R15-20230925","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am J Psychiatry"},{"key":"R16-20230925","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"R17-20230925","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/can.2017.0043","article-title":"Therapeutic effects of prolonged cannabidiol treatment on psychological symptoms and cognitive function in regular cannabis users: a pragmatic open-label clinical trial","volume":"3.1","author":"Solowij","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"key":"R18-20230925","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881117735684","article-title":"Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: a case series","volume":"32","author":"Schipper","year":"2018","journal-title":"J Psychopharmacol (Oxf)"},{"key":"R19-20230925","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","article-title":"Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial","volume":"75","author":"Bhattacharyya","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"R20-20230925","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41398-019-0534-2","article-title":"Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis","volume":"9","author":"Wilson","year":"2019","journal-title":"Transl Psychiatry"},{"issue":"(Suppl 1)","key":"R21-20230925","doi-asserted-by":"crossref","first-page":"S28\u2013S","DOI":"10.1093\/schbul\/sby014.067","article-title":"Effect of cannabidiol on symptoms, distress and neurophysiological abnormalities in clinical high-risk for psychosis patients: a placebo-controlled study","volume":"44","author":"Bhattacharyya","year":"2018","journal-title":"Schizophr Bull"},{"issue":"(Suppl 1)","key":"R22-20230925","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1093\/schbul\/sby018.939","article-title":"Cannabidiol induced modulation of mediotemporal activity during a verbal memory task in first-episode psychosis","volume":"44","author":"O\u2019Neill","year":"2018","journal-title":"Schizophr Bull"},{"key":"R27-20230925","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","article-title":"A randomised controlled trial of vaporised Delta(9)-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects","volume":"269","author":"Solowij","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R28-20230925","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"R29-20230925","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"Lancet Psychiatr"}],"container-title":["Current Opinion in Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/YCO.0000000000000596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T10:53:12Z","timestamp":1695639192000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/YCO.0000000000000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/yco.0000000000000596","relation":{},"ISSN":["0951-7367","1473-6578"],"issn-type":[{"value":"0951-7367","type":"print"},{"value":"1473-6578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}